Using this approach, several advantages have come forward from the work of Lilienthal et al by targeting the CD22 receptor on chronic lymphocytic leukaemia (CLL) with the recombinant antibody fragment SGIII fused to a DAPk1 mutant lacking the native auto-inhibitory CaM domain [47]. Here, DAPK1 is linked to B-cell chronic lymphocytic leukemia.